Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022
Share
Chi Sheng Pharma & Biotech Co., Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 289.61 million compared to TWD 267.07 million a year ago. Revenue was TWD 289.61 million compared to TWD 267.07 million a year ago. Net income was TWD 47.09 million compared to TWD 22.28 million a year ago. Basic earnings per share from continuing operations was TWD 0.83 compared to TWD 0.39 a year ago. Diluted earnings per share from continuing operations was TWD 0.82 compared to TWD 0.39 a year ago.
For the nine months, sales was TWD 853.73 million compared to TWD 761.46 million a year ago. Revenue was TWD 853.73 million compared to TWD 761.46 million a year ago. Net income was TWD 99.62 million compared to TWD 46.79 million a year ago. Basic earnings per share from continuing operations was TWD 1.75 compared to TWD 0.82 a year ago. Diluted earnings per share from continuing operations was TWD 1.74 compared to TWD 0.82 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 
